Exane Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Exane Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-27,078	Closed	-$3.55M	–	47
2019 Q2	$3.55M	Buy	+27,078	New	+$3.49M	1.58%	20
2019 Q1	–	Sell	-14,758	Closed	-$1.44M	–	110
2018 Q4	$1.44M	Sell	14,758 -123,162	-89%	-$14.6M	0.84%	23
2018 Q3	$19.2M	Buy	+137,920	New	+$17.3M	6%	3
2018 Q2	–	Sell	-112,999	Closed	-$12.6M	–	181
2018 Q1	$12.6M	Buy	+112,999	New	+$13.5M	3.78%	8
2017 Q4	–	Sell	-79,865	Closed	-$11.2M	–	155
2017 Q3	$11.2M	Sell	79,865 -12,908	-14%	-$1.75M	2.19%	17
2017 Q2	$11.3M	Buy	+92,773	New	+$10.8M	3.52%	12
2016 Q4	–	Sell	-100,933	Closed	-$12.4M	–	43
2016 Q3	$12.4M	Sell	100,933 -40,521	-29%	-$5.22M	3.88%	9
2016 Q2	$16.5M	Buy	+141,454	New	+$20.1M	6.41%	4

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Exane Asset Management's ALXN Position: Q3 2019 in Review

Exane Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 27,078 shares — an estimated $3.55M sold.

Exane Asset Management first reported a position in ALXN in Q2 2016 and held it in 8 quarters. The position peaked at $19.2M in Q3 2018. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Exane Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Exane Asset Management sold 27,078 Alexion Pharmaceuticals shares in Q3 2019, an estimated $3.55M.
Exane Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 8 quarters.
Exane Asset Management's Alexion Pharmaceuticals position peaked at $19.2M in Q3 2018.
646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Exane Asset Management's 13F filing for Q3 2019, filed 24 Oct 2019.